Efficacy and Immune Effects of Anakinra Prophylaxis for Neurologic Toxicity and Cytokine Release Syndrome in Patients with Lymphoma Receiving Axicabtagene Ciloleucel
Demographics (4)
- AGE_ONSET - Disease onset age (phv00543415.v1.p1)
- SEX - Self-reported sex (phv00543414.v1.p1)
- SEX - Biological sex (phv00543410.v1.p1)
- TIMEPOINT - Timing of CAR infusion, day of or 7 days post CAR infusion (phv00543422.v1.p1)
Disease Events (1)
- DISEASE - Case control status of the subject for lymphoma (phv00543417.v1.p1)
Other (13)
- ANALYTE_TYPE - Analyte type (phv00543420.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00543419.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00543409.v1.p1)
- IS_TUMOR - Tumor status (phv00543421.v1.p1)
- POOLED_SUBJECT_ID - ID of th e subject pool in which the subject has been included (phv00556277.v1.p1)
- SAMPLE_ID - Sample ID (phv00543418.v1.p1)
- SAMPLE_ID - Sample ID (phv00543412.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00543424.v1.p1)
- SORTING_STRATEGY - Indicates cells sorted from sample (phv00543423.v1.p1)
- SUBJECT_ID - Subject ID (phv00543413.v1.p1)
- SUBJECT_ID - Subject ID (phv00543408.v1.p1)
- SUBJECT_ID - Subject ID (phv00543411.v1.p1)
- TREATMENT - Disease treatment received by subject (phv00543416.v1.p1)